Comments
AstraZeneca has struck a partnership deal worth up to $500 million with Eli Lilly for the British group’s experimental Alzheimer’s drug, which is set to enter late-stage Phase III development.
AstraZeneca had said in May that it was looking to find a partner for its so-called BACE inhibitor drug, AZD3293.
Under the terms of the agreement, Lilly will pay AstraZeneca up to $500 million, depending on the progress in the drug’s development. AstraZeneca said on Tuesday it expected to receive the first payment of $50 million in the first half of 2015.
The companies will share equally all costs for the development and commercialisation of AZD3293, as well as net global revenues after its launch.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.